Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.
Standard
Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy. / Erttmann, Rudolf; Bielack, S; Landbeck, G.
In: CANCER CHEMOTH PHARM, Vol. 15, No. 2, 2, 1985, p. 101-104.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.
AU - Erttmann, Rudolf
AU - Bielack, S
AU - Landbeck, G
PY - 1985
Y1 - 1985
N2 - Kinetics of 7-hydroxy-methotrexate (7-OH-MTX) excretion after high-dose methotrexate (MTX) (12 g/m2) therapy were monitored in 93 consecutive drug cycles of 19 adolescent patients with osteosarcoma. A reversed-phase HPLC method was used. Serum elimination was found to be monophasic with a mean half-life of 5.5 h. Shortly after the 4-h MTX infusion period 7-OH-MTX levels exceeded those of the parent compound. By 12 h after MTX infusion 7-OH-MTX levels were 16.5 times higher than those of MTX itself. Autostimulation of MTX metabolism leading to enhanced 7-OH-MTX production after repeated drug cycles was not observed. The production of 7-OH-MTX decreased significantly from the first to the last high-dose MTX cycle of the adjuvant chemotherapy protocol.
AB - Kinetics of 7-hydroxy-methotrexate (7-OH-MTX) excretion after high-dose methotrexate (MTX) (12 g/m2) therapy were monitored in 93 consecutive drug cycles of 19 adolescent patients with osteosarcoma. A reversed-phase HPLC method was used. Serum elimination was found to be monophasic with a mean half-life of 5.5 h. Shortly after the 4-h MTX infusion period 7-OH-MTX levels exceeded those of the parent compound. By 12 h after MTX infusion 7-OH-MTX levels were 16.5 times higher than those of MTX itself. Autostimulation of MTX metabolism leading to enhanced 7-OH-MTX production after repeated drug cycles was not observed. The production of 7-OH-MTX decreased significantly from the first to the last high-dose MTX cycle of the adjuvant chemotherapy protocol.
M3 - SCORING: Zeitschriftenaufsatz
VL - 15
SP - 101
EP - 104
JO - CANCER CHEMOTH PHARM
JF - CANCER CHEMOTH PHARM
SN - 0344-5704
IS - 2
M1 - 2
ER -